2025-10-03 - Analysis Report
Okay, here's a comprehensive analysis of Intuitive Surgical (ISRG), based on the data you provided.  The report is in English, starting with key figures and then expanding into a more detailed analysis.

**Report on Intuitive Surgical (ISRG)**

**0. Executive Summary**

ISRG, Intuitive Surgical Inc., specializes in robotic surgical systems.  While ISRG's recent cumulative return lags the S&P 500, positive analyst sentiment, recent product upgrades, and strong revenue growth suggest a promising outlook, though some caution is warranted due to market risk indicators.
**1. Performance vs. S&P 500 (VOO)**

*   **Cumulative Return ISRG:** 66.08%
*   **Cumulative Return VOO:** 97.56%
*   **Return Differential (ISRG - VOO):** -31.49%
*   **Relative Differential Percentile:** 2.0% (Indicates ISRG's underperformance is near the lowest end of its historical range compared to VOO).

**Analysis:** ISRG has significantly underperformed the S&P 500 over the period examined. The relative differential percentile suggests this underperformance is notable compared to its historical trends.
**Alpha, Beta Analysis**

| Year       | CAGR    | MDD     | Alpha   | Beta   | Cap(B) |
|------------|---------|---------|---------|--------|--------|
| 2015-2017  | 68.0%   | 77.6%   | 40.0%   | -0.1   | 43.8   |
| 2016-2018  | 64.0%   | 72.2%   | 49.0%   | -0.0   | 57.5   |
| 2017-2019  | 54.0%   | 72.2%   | 31.0%   | 0.2    | 71.0   |
| 2018-2020  | -6.0%   | 80.4%   | -29.0%  | 0.3    | 98.2   |
| 2019-2021  | 29.0%   | 80.4%   | -18.0%  | 0.6    | 129.4  |
| 2020-2022  | -23.0%  | 80.4%   | -22.0%  | 1.2    | 95.5   |
| 2021-2023  | -17.0%  | 77.5%   | -18.0%  | 1.7    | 121.5  |
| 2022-2024  | 36.0%   | 77.5%   | 15.0%   | 1.7    | 187.9  |
| 2023-2025  | 28.0%   | 72.7%   | -34.0%  | 0.8    | 160.1  |

**Analysis:**

*   **CAGR:** Fluctuates significantly across different periods, indicating volatility in returns.
*   **MDD (Maximum Drawdown):** Consistently high, reflecting substantial downside risk.
*   **Alpha:**  Mostly negative in recent periods, suggesting underperformance relative to its benchmark (S&P 500). Positive alpha in earlier periods.
*   **Beta:** Generally low (close to 0) but trending upwards over time. Higher beta indicates increased sensitivity to market movements.
*   **Cap(B):** Market capitalization has generally increased over time, reflecting overall company growth.

**2. Recent Stock Price Movement**

*   **Current Price:** 444.50
*   **Last Market Data:** {'price': 443.01, 'previousClose': 438.04, 'change': 1.13}
*   **5-Day Moving Average:** 443.61
*   **20-Day Moving Average:** 447.20
*   **60-Day Moving Average:** 477.16

**Analysis:** The stock price is currently trading below its 20-day and 60-day moving averages, suggesting potential short-term downward momentum.  However, the recent price increase (Last Market Data Change: 1.13) indicates some buying pressure.

**3. Technical Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 35.93 (Approaching oversold territory)
*   **PPO:** 0.26
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.70)
*   **20-Day Relative Differential Change:** 0.7 (+): Short-term increase
*   **Expected Return:** 616.0% (Long-term, relative to S&P 500)

**Analysis:**

*   The high MRI suggests the market is considered relatively safe for investment overall.
*   The RSI indicates the stock *may* be approaching an oversold condition, potentially signaling a buying opportunity.
*   The PPO is a momentum indicator that shows the percentage difference between two moving averages. A small positive value, like 0.26, suggests slight upward momentum, but not particularly strong.
*   The Hybrid Signal advises a partial buy, but with caution, aligning with the medium MRI.
*   The significant expected return (616%) suggests substantial potential upside over the long term *relative to the S&P 500.* However, such a high figure should be viewed with skepticism.

**4. Recent News & Significant Events**

*   **Positive Analyst Coverage:** Zacks highlights broker recommendations to invest in ISRG.
*   **Dividend Potential:** Motley Fool suggests ISRG could soar in 2026.
*   **AI-Powered Upgrades:** ISRG unveils AI-powered da Vinci 5 upgrades, indicating innovation and potential for improved surgical outcomes.
*   **Competition:** News about SS Innovations International's growth suggests increasing competition in the robotic surgery market.
*   **Expanded Indications:** ISRG expands SP indications, potentially increasing market reach.
*   **Analyst Price Target Adjustment:** Goldman Sachs adjusts price target downward but maintains a "Buy" rating, suggesting continued confidence in the company.

**Analysis:** Recent news is mostly positive, focusing on analyst recommendations, product upgrades, and market expansion. The news about competitors could be a potential watch-out.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.94)
*   **Target Price:** Average: $580.10, High: $685.00, Low: $350.00

**Analysis:** The analyst consensus is strongly positive, with a "Buy" rating and a significant average target price considerably higher than the current price. The wide range between the high and low target prices indicates uncertainty among analysts.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-07-23 | 1.84 | 2.44 B$   |
| 2025-04-23 | 1.95 | 2.25 B$   |
| 2024-10-18 | 1.59 | 2.04 B$   |
| 2024-07-19 | 1.48 | 2.01 B$   |
| 2025-07-23 | 1.48 | 2.01 B$   |

**Analysis:** Both EPS and Revenue have generally shown an upward trend, especially recently. This suggests positive business momentum.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-06-30   | $2.44B    | 66.31%        |
| 2025-03-31   | $2.25B    | 64.69%        |
| 2024-12-31   | $2.41B    | 68.04%        |
| 2024-09-30   | $2.04B    | 67.41%        |
| 2024-06-30   | $2.01B    | 68.30%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE       |
|--------------|-----------|-----------|
| 2025-06-30   | $17.85B   | 3.69%     |
| 2025-03-31   | $17.11B   | 4.08%     |
| 2024-12-31   | $16.43B   | 4.17%     |
| 2024-09-30   | $15.58B   | 3.63%     |
| 2024-06-30   | $14.71B   | 3.58%     |

**Analysis:**

*   **Revenue:** Consistent growth in revenue quarter over quarter
*   **Profit Margin:** Remains high and relatively stable, indicating strong pricing power and efficient operations.
*   **Equity:**  Increasing equity suggests the company is growing its asset base.
*   **ROE (Return on Equity):**  Fluctuates, but generally remains healthy, indicating efficient use of shareholder equity to generate profits.

**7. Overall Analysis and Conclusion**

Intuitive Surgical (ISRG) presents a mixed picture.

**Positive Factors:**

*   **Strong Revenue and Earnings Growth:** Recent quarters show consistent growth in both revenue and EPS.
*   **High Profitability:**  Maintains high profit margins, indicating strong competitive advantages.
*   **Positive Analyst Sentiment:**  Consensus "Buy" rating and high target prices.
*   **Product Innovation:**  The introduction of AI-powered upgrades to the da Vinci system positions the company for future growth.
*   **High Market Risk Indicator:** Suggests favorable overall market conditions.

**Negative Factors/Cautions:**

*   **Underperformance vs. S&P 500:**  ISRG has significantly underperformed the S&P 500 recently.
*   **Rising Beta:** Indicates increased sensitivity to market fluctuations.
*   **Competition:** Increasing competition in the robotic surgery market could impact future growth.
*   **High MDD:** Suggests high risks.
*   **Hybrid signal:** Cautious signal

**Overall:**

ISRG appears to be a company with solid fundamentals and positive growth prospects. However, the recent underperformance relative to the S&P 500 and the increasing beta warrant caution. The high expected return should be viewed with scrutiny. An investment in ISRG would be a higher-risk, higher-potential-reward play compared to simply investing in the S&P 500. Investors should carefully weigh these factors and conduct further due diligence before making an investment decision.
